Trials / Completed
CompletedNCT05815862
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
A Multi-cohort, Randomized, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AL2846 Capsules in Treated Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer. Objective response rate (ORR) and progression-free survival (PFS) are the primary endpoints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL2846 capsule | AL2846 is a multi-target tyrosine kinase inhibitor. |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2025-08-20
- Completion
- 2025-08-20
- First posted
- 2023-04-18
- Last updated
- 2025-08-29
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05815862. Inclusion in this directory is not an endorsement.